Inclusion Criteria:

- Advanced renal cell carcinoma of a histological or cytological confirmation of clear
cell (or with a component of clear cell) renal carcinoma that have previously
progressed on or were intolerant to first-line therapy with sunitinib, sorafenib,
pazopanib, axitinib, bevacizumab, or cytokine therapy.

- Prior nephrectomy (partial or total)

- Patients with at least one measurable lesion at baseline as per the RECIST 1.0
criteria

- Karnofsky Performance Status ≥ 70%

Exclusion Criteria:

- Patients who have received more than one prior treatment regimen for metastatic
renal-cell carcinoma

- Patients who have received adjuvant therapy for RCC

- Patients who have previously received systemic mTOR inhibitors (eg, sirolimus,
temsirolimus, everolimus)

- Patients with brain metastases

- Patients within 4 weeks post-major surgery, open biopsy, or significant traumatic
injury to avoid wound healing complications.

- Patients who had radiation therapy within 4 weeks prior to start of study treatment
(palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study
treatment start).

- Concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
diabetes, active or uncontrolled infection) that could cause unacceptable safety
risks or compromise compliance with the protocol

Other protocol-defined inclusion/exclusion criteria may apply